-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Venadaparib in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Venadaparib in Gastric Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Venadaparib in Gastric Cancer Drug Details: IDX-1197 (NOV1401) is under development for...
-
Product Insights
Wesley MC – 833 North Vassar Avenue Rehabilitation Hospital – Kansas
Equip yourself with the essential tools needed to make informed and profitable decisions with our Wesley MC – 833 North Vassar Avenue Rehabilitation Hospital – Kansas report. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Reasons to buy Acquire a thorough understanding...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MC-232 in Hidradenitis Suppurativa
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MC-232 in Hidradenitis Suppurativa report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MC-232 in Hidradenitis Suppurativa Drug Details: MC2-32 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MC-225 in Uremic (Renal) Pruritus
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MC-225 in Uremic (Renal) Pruritus report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MC-225 in Uremic (Renal) Pruritus Drug Details: MC-225 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MC-001 in Spinal Cord Injury
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MC-001 in Spinal Cord Injury report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.MC-001 in Spinal Cord InjuryDrug Details:MC-001 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MC-232 in Plaque Psoriasis (Psoriasis Vulgaris)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. MC-232 in Plaque Psoriasis (Psoriasis Vulgaris) Drug Details: MC-232 is under development for the treatment...
-
Product Insights
NewOcular Melanoma – Drugs In Development, 2024
Empower your strategies with our Ocular Melanoma – Drugs In Development, 2024 report and make more profitable business decisions. Ocular melanoma is an extremely rare form of cancer that affects the eye with an incidence of 5 per million adults. Although rare, it is the most common primary cancer of the eye in adults. Primary means that the cancer began at that site (in this case the eye) and did not spread there from another part of the body The Ocular...
-
Product Insights
NewSimplexvirus (HSV) Infections – Drugs In Development, 2024
Empower your strategies with our Simplexvirus (HSV) Infections – Drugs In Development, 2024 report and make more profitable business decisions. Herpes simplex virus (HSV) infections, also known as simplexvirus infections, are caused by two types of viruses: HSV-1 and HSV-2. HSV-1 typically causes oral herpes, manifesting as cold sores around the mouth, while HSV-2 is primarily responsible for genital herpes. However, both types can cause infections in either location. These infections are highly contagious and transmitted through direct contact with an...
-
Product Insights
NewUveal Melanoma – Drugs In Development, 2024
Empower your strategies with our Uveal Melanoma – Drugs In Development, 2024 report and make more profitable business decisions. Uveal melanoma, the most common intraocular tumor, is a disease in which malignant (cancer) cells are found in the part of the eye called the uvea. The uvea contains cells called melanocytes. When these cells become cancerous, the cancer is called a melanoma. Symptoms include a dark spot on the iris, glaucoma, eye pain, and eye redness. Uveal melanoma is more common...